

Jillian Tsai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7372268/publications.pdf>

Version: 2024-02-01

88
papers

1,899
citations

331538

21
h-index

302012

39
g-index

88
all docs

88
docs citations

88
times ranked

2829
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2023, 52, 71-86.	0.9	16
2	Impact of the Early COVID-19 Pandemic on Gender Participation in Academic Publishing in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2022, 7, 100845.	0.6	4
3	Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. <i>JAMA Oncology</i> , 2022, 8, 364.	3.4	39
4	Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study. <i>Oral Oncology</i> , 2022, 126, 105781.	0.8	3
5	The Role of Ablative Radiotherapy in Older Adults With Limited Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2022, 32, 135-141.	1.0	2
6	Is representation enough or should we be targeting equitable inclusion?. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 429-430.	12.5	4
7	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
8	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	1.4	11
9	Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia. <i>International Journal of Cancer</i> , 2022, 151, 1033-1046.	2.3	18
10	Practical Considerations for the Implementation of a Stereotactic Body Radiation Therapy Program for Oligo-Metastases. <i>Advances in Radiation Oncology</i> , 2021, 6, 100499.	0.6	0
11	Ipsilateral radiation for squamous cell carcinoma of the tonsil: American Radium Society appropriate use criteria executive summary. <i>Head and Neck</i> , 2021, 43, 392-406.	0.9	17
12	Metastatic Disease as a Distinct Discipline in Radiation Oncology. <i>JAMA Oncology</i> , 2021, 7, 21.	3.4	8
13	Trends in Radiation Therapy for Bone Metastases, 2015 to 2017: Choosing Wisely in the Era of Complex Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 923-931.	0.4	10
14	Metastasis-directed therapy for oligometastasis and beyond. <i>British Journal of Cancer</i> , 2021, 124, 136-141.	2.9	16
15	Systematic review of postoperative therapy for resected squamous cell carcinoma of the head and neck: Executive summary of the American Radium Society appropriate use criteria. <i>Head and Neck</i> , 2021, 43, 367-391.	0.9	9
16	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239
17	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98
18	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. <i>Head and Neck</i> , 2021, 43, 1056-1062.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. <i>International Journal of Cancer</i> , 2021, 149, 139-148.	2.3	1
20	Nongaussian Intravoxel Incoherent Motion Diffusion Weighted and Fast Exchange Regime Dynamic Contrast-Enhanced-MRI of Nasopharyngeal Carcinoma: Preliminary Study for Predicting Locoregional Failure. <i>Cancers</i> , 2021, 13, 1128.	1.7	4
21	Emerging Paradigm of Consolidative Thoracic Radiotherapy in Oligometastatic NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 120-123.	1.0	3
22	The Top 10 Downloads of 2020 in ASTRO's Advances in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2021, 6, 100678.	0.6	0
23	Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 463-469.	0.6	11
24	Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence—Reply. <i>JAMA Oncology</i> , 2021, 7, 783.	3.4	0
25	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. <i>Cancer Medicine</i> , 2021, 10, 5163-5174.	1.3	11
26	Evaluating Bias in Speaker Introductions at the American Society for Radiation Oncology Annual Meeting. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 303-311.	0.4	9
27	Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. <i>Current Oncology</i> , 2021, 28, 2409-2419.	0.9	8
28	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. <i>Cancer Medicine</i> , 2021, 10, 4221-4227.	1.3	8
29	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. <i>JAMA Network Open</i> , 2021, 4, e2113205.	2.8	34
30	Top 20 Peer Reviewers for 2020. <i>Advances in Radiation Oncology</i> , 2021, 6, 100709.	0.6	0
31	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	1.5	10
32	The effect of short radiation treatment breaks on chemoradiotherapy for oropharyngeal cancers. <i>Head and Neck</i> , 2021, 43, 3796-3809.	0.9	0
33	Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017. <i>JAMA Network Open</i> , 2021, 4, e2125328.	2.8	7
34	Patterns of Radiotherapy Use and Outcomes in Head and Neck Soft-Tissue Sarcoma in a National Cohort. <i>Laryngoscope</i> , 2020, 130, 120-127.	1.1	5
35	Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. <i>Cancer</i> , 2020, 126, 444-452.	2.0	38
36	Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. <i>International Journal of Cancer</i> , 2020, 147, 107-115.	2.3	14

#	ARTICLE	IF	CITATIONS
37	Addressing the Impact of Systemic Racism in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2020, 5, 791-792.	0.6	1
38	The International Response to the Coronavirus Disease (2019) COVID-19 Pandemic in Radiation Oncology. <i>Advances in Radiation Oncology</i> , 2020, 5, 523-524.	0.6	2
39	Patterns and Perceptions of "Away" Rotations Among Radiation Oncology Residency Applicants. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 1007-1011.	0.4	19
40	Scholarly Publishing in the Wake of COVID-19. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 491-495.	0.4	12
41	Prognostic significance of human papillomavirus and <scp>Epstein-Bar</scp> virus in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 2364-2374.	0.9	12
42	Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 30-34.	0.9	2
43	To Shy Away From Chemotherapy Is to Compromise. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 616-617.	0.4	0
44	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	0.8	16
45	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind" A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	2.0	24
46	Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. <i>Cancer</i> , 2020, 126, 1905-1916.	2.0	31
47	Efforts to Reduce the Impact of Coronavirus Disease 2019 Outbreak on Radiation Oncology in Taiwan. <i>Advances in Radiation Oncology</i> , 2020, 5, 534-537.	0.6	14
48	Palliative Radiation Therapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits. <i>Advances in Radiation Oncology</i> , 2020, 5, 589-594.	0.6	44
49	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	0.9	24
50	The Year 2020 in Review at ASTRO's Advances. <i>Advances in Radiation Oncology</i> , 2020, 5, 1091-1092.	0.6	0
51	Predicting radiation dosimetric distribution in different regions of the jaw in patients receiving radiotherapy for squamous cell carcinoma of the tonsil. <i>Head and Neck</i> , 2019, 41, 3604-3611.	0.9	5
52	Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. <i>Head and Neck</i> , 2019, 41, 3551-3563.	0.9	16
53	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32
54	Big Data in Cancer Research: Real-World Resources for Precision Oncology to Improve Cancer Care Delivery. <i>Seminars in Radiation Oncology</i> , 2019, 29, 306-310.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Microsatellite Instability and Adjuvant Chemotherapy in Stage II Colon Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 573-580.	0.6	26
56	Reducing the Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus-Associated Oropharyngeal Carcinoma Being Treated With Primary Chemoradiotherapy at Memorial Sloan Kettering Cancer Center. <i>Practical Radiation Oncology</i> , 2019, 9, 98-101.	1.1	23
57	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 130-142.	0.8	40
58	Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. <i>Head and Neck</i> , 2019, 41, 1418-1426.	0.9	21
59	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). <i>International Journal of Particle Therapy</i> , 2019, 5, 1-10.	0.9	10
60	Use of Preoperative Radiation Therapy in Early-stage and Locally Advanced Breast Cancer. <i>Cureus</i> , 2019, 11, e5748.	0.2	0
61	Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks. <i>International Journal of Cancer</i> , 2018, 142, 2485-2490.	2.3	7
62	Lymph Node Yield as Quality Metric for Clinically NO Oral Cancer—Reply. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 386.	1.2	0
63	Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. <i>Cancer</i> , 2018, 124, 482-490.	2.0	17
64	Impact of Insurance Coverage on Outcomes in Primary Breast Sarcoma. <i>Sarcoma</i> , 2018, 2018, 1-11.	0.7	8
65	Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2018, 143, 3262-3272.	2.3	18
66	Proton Therapy for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 28.	1.3	46
67	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	2.4	23
68	Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. <i>International Journal of Particle Therapy</i> , 2018, 4, 10-19.	0.9	9
69	The NEAT Predictive Model for Survival in Patients with Advanced Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1433-1443.	1.3	21
70	Internal and external generalizability of temporal dose-response relationships for xerostomia following IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 200-206.	0.3	5
71	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017, 122, 146-151.	0.3	45
72	The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2017, 45, 595-600.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 758-766.	0.4	7
74	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. <i>JAMA Oncology</i> , 2017, 3, 1487.	3.4	146
75	The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience. <i>Oral Oncology</i> , 2017, 64, 44-51.	0.8	159
76	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , 2017, 123, 1345-1353.	2.0	20
77	Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1049.	1.2	15
78	Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 549-559.	0.4	19
79	Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, 254-259.	1.1	17
80	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	1.1	16
81	Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT). <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1408-1413.	0.7	26
82	Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT. <i>Oral Oncology</i> , 2016, 58, 27-31.	0.8	8
83	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	2.6	44
84	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 53, 67-73.	0.8	44
85	Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck. <i>International Journal of Particle Therapy</i> , 2016, 3, 421-428.	0.9	2
86	Radiographic osteoradionecrosis of the jaw with intact mucosa: Proposal of clinical guidelines for early identification of this condition. <i>Oral Oncology</i> , 2015, 51, e93-e96.	0.8	19
87	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. <i>Oral Oncology</i> , 2015, 51, 957-962.	0.8	67
88	Dose painting with Gamma Knife: Two techniques for delivering different doses to areas of recurrent or residual tumor after resection of brain metastases. <i>Practical Radiation Oncology</i> , 2015, 5, 390-397.	1.1	0